PacBio Announces First Quarter 2024 Financial Results [Yahoo! Finance]
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: Yahoo! Finance
First quarter results: Revenue of $38.8 million compared with $38.9 million in the prior-year period. Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. Instrument revenue in the first quarter of 2024 included 28 Revio TM sequencing systems. Consumables revenue of $16.0 million compared with $14.0 million in the prior-year period. Service and other revenue of $3.8 million compared with $4.2 million in the prior-year period. Gross profit for the first quarter of 2024 was $11.3 million , representing a 16% increase compared with $9.8 million for the first quarter of 2023 and a gross margin of 29% in the first quarter of 2024 compared to 25% for the first quarter of 2023. Operating expenses totaled $92.6 million for the first quarter of 2024, compared to $101.0 million for the first quarter of 2023. Operating expenses for the first quarter of 2024 and the first quarter of 2023 included non-cash share-based compensation of $17.4 million
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Morgan Stanley from $10.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases [Yahoo! Finance]Yahoo! Finance
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare DiseasesPR Newswire
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Piper Sandler from $6.50 to $2.00. They now have a "neutral" rating on the stock.MarketBeat
PACB
Earnings
- 5/9/24 - In-Line
PACB
Sec Filings
- 5/9/24 - Form S-3ASR
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- PACB's page on the SEC website